Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,329.10",
    "chg": 27.8,
    "chgp": "2.14%",
    "dir": 1,
    "prev_price": "1,301.30",
    "mcapval": "111,367.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Jun 24, 02:49 PM",
    "curr_time": "14:51 PM",
    "last_traded_at": "Jun 24, 02:49 PM IST",
    "bse_nse_vol": "29.48 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 24, 2026",
    "traded_date_str": "2026 06 24",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 25.87 vs Industry's 34.68: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-amid-nifty-50-membership-4069921",
        "imagepath": "",
        "date": "2026-06-24 09:21:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 25.87, which is approximately 25.4% lower than the Pharmaceuticals &amp; Biotechnology industry average of 34.68. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to its peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be valued more cautiously. Investors might wonder <a href=\"https://www.marketsmojo...."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-signal-bullish-outlook-4068079",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_technicaldot_4068079.png",
        "date": "2026-06-23 08:04:51",
        "description": "Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting a nuanced but positive outlook for the pharmaceutical giant amid a volatile market backdrop."
      },
      {
        "title": "P/E at 25.29 vs Industry's 34.06: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-4066828",
        "imagepath": "",
        "date": "2026-06-22 09:21:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 25.29, which is approximately 25.7% below the Pharmaceuticals & Biotechnology industry average of 34.06. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives risks not fully reflected in the broader sector valuation. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be valued more conservatively de..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-hold-4063329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_mojoScore_4063329.png",
        "date": "2026-06-19 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "P/E at 25.28 vs Industry's 33.88: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amidst-nifty-50-membership-4062820",
        "imagepath": "",
        "date": "2026-06-19 09:21:19",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of 25.28 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the industry average of 33.88, indicating a valuation discount of roughly 25%. This divergence suggests that the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, so this discount merits close attention. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Lab..."
      },
      {
        "title": "P/E at 25.24 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-performance-4060681",
        "imagepath": "",
        "date": "2026-06-18 09:21:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 25.24, notably below the Pharmaceuticals &amp; Biotechnology industry average of 33.60. This represents a discount of approximately 24.9%, suggesting the market is pricing in either subdued growth expectations or risk factors relative to peers. Such a valuation gap is particularly striking given the company’s large-cap status and established market presence. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys L..."
      },
      {
        "title": "P/E at 25.42 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4058486",
        "imagepath": "",
        "date": "2026-06-17 09:21:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 25.42 stands well below the sector average of 33.60, indicating a valuation discount of nearly 24%. This gap suggests the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or reflecting concerns over competitive pressures within the Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, so the discount may imply a more conservative stance on <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk..."
      },
      {
        "title": "P/E at 25.46 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4055537",
        "imagepath": "",
        "date": "2026-06-16 09:21:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 25.46 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the industry average of 33.60, signalling a valuation discount of nearly one-quarter relative to its peers. This gap suggests the market is pricing in either a more cautious outlook on earnings growth or risk factors specific to the company. In contrast, many large-cap pharmaceutical stocks continue to command premium multiples, reflecting expectations of robust innovation pipelines or steady cash flows. The discount may also reflect recent performance trends or sector rotation effects. <a href=\"https://www.marketsmojo.com/stocks..."
      },
      {
        "title": "P/E at 25.34 vs Industry's 33.79: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4053732",
        "imagepath": "",
        "date": "2026-06-15 09:21:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable prestige and market influence on Dr Reddys Laboratories Ltd. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a barometer for the Indian equity market’s health and investor confidence. Inclusion ensures heightened visibility among domestic and global institutional investors, index funds, and exchange-traded funds (ETFs), which often track or benchmark against the Nifty 50.</p>\n                <p>Dr Reddys’ market capitalisation stands at a robust ₹1,06,320 crores, firmly placing it in the large-cap category. This scale not only supports liquidity but also stabilises its weight within ..."
      }
    ],
    "total": 591,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Considering The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending On June 30 2026",
      "datetime": "22-Jun-2026",
      "details": "Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "22-Jun-2026",
      "details": "Intimation regarding Closure of Trading window",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "20-Jun-2026",
      "details": "Newspaper Publication",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "22 Jul 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 25.87 vs Industry's 34.68: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-24 09:21:13

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 25.87, which is approximately 25.4% lower than the Pharmaceuticals & Biotechnology industry average of 34.68. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to its peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be valued more cautiously. Investors might wonder Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook

2026-06-23 08:04:51

Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting a nuanced but positive outlook for the pharmaceutical giant amid a volatile market backdrop.

Read full news article

P/E at 25.29 vs Industry's 34.06: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-22 09:21:18

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 25.29, which is approximately 25.7% below the Pharmaceuticals & Biotechnology industry average of 34.06. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives risks not fully reflected in the broader sector valuation. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, but Dr Reddys Laboratories Ltd appears to be valued more conservatively de...

Read full news article

Dr Reddys Laboratories Ltd is Rated Hold

2026-06-19 10:10:04

Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

P/E at 25.28 vs Industry's 33.88: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-19 09:21:19

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of 25.28 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.88, indicating a valuation discount of roughly 25%. This divergence suggests that the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, so this discount merits close attention. Dr Reddys Lab...

Read full news article

P/E at 25.24 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-18 09:21:52

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 25.24, notably below the Pharmaceuticals & Biotechnology industry average of 33.60. This represents a discount of approximately 24.9%, suggesting the market is pricing in either subdued growth expectations or risk factors relative to peers. Such a valuation gap is particularly striking given the company’s large-cap status and established market presence. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys L...

Read full news article

P/E at 25.42 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-17 09:21:37

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of Dr Reddys Laboratories Ltd at 25.42 stands well below the sector average of 33.60, indicating a valuation discount of nearly 24%. This gap suggests the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or reflecting concerns over competitive pressures within the Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, so the discount may imply a more conservative stance on Read full news article

P/E at 25.46 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-16 09:21:00

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 25.46 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.60, signalling a valuation discount of nearly one-quarter relative to its peers. This gap suggests the market is pricing in either a more cautious outlook on earnings growth or risk factors specific to the company. In contrast, many large-cap pharmaceutical stocks continue to command premium multiples, reflecting expectations of robust innovation pipelines or steady cash flows. The discount may also reflect recent performance trends or sector rotation effects. Read full news article

P/E at 25.34 vs Industry's 33.79: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-15 09:21:04

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable prestige and market influence on Dr Reddys Laboratories Ltd. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a barometer for the Indian equity market’s health and investor confidence. Inclusion ensures heightened visibility among domestic and global institutional investors, index funds, and exchange-traded funds (ETFs), which often track or benchmark against the Nifty 50.

Dr Reddys’ market capitalisation stands at a robust ₹1,06,320 crores, firmly placing it in the large-cap category. This scale not only supports liquidity but also stabilises its weight within ...

Read full news article

View All News